|Description||Levonantrado is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. Levonantrado is around 30x more potent than THC, and exhibits antiemetic and analgesic effects via activation of CB1 and CB2cannabinoid receptors. Now, Levonantradol is not used in medicine,but it is widely used in research into the potential therapeutic applications of cannabinoids.|
|Synonyms||CP 50,556-1; CP-50,556-1;UNII-V92884KHRI;[(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate;hydrochloride;71048-87-8(base)|
|Solubility||Soluble in DMSO|
|Application||used in research into the potential therapeutic applications of cannabinoids|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
Rimonabant Hydrochloride, used as a tool to investigate CB receptor properties, it is a selective antagonist of cannabinoid CB1 receptor (Ki = 1.98 nM) and inve...
CB1-IN-1 is an antagonist of cannabinoid receptor type 1 (CB1R) located in the peripheral nervous system, which may be significant for pain modulation.
MDA 19, a benzohydrazide derivative, has been found to be a CB2 receptor agonist and could be useful in reducting the Attenuates tactile allodynia of rats. IC50...
AM 1714, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor.
L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in ...
GSK-554418A is a azaindole Cannabinoid receptor type 2 (CB2) agonist. It can be used for the treatment of chronic pain.
Taranabant is a cannabinoid 1 receptor inverse agonist ( IC50 =0.3 nM).
Otenabant HCl is a selective and high affinity antagonist of CB1 with Ki value of 0.7 nM.
CB-13 is a dual agonist of the CB1 (IC50 = 15 nM) and CB2 (IC50 = 98 nM) receptors, displays antihyperalgesic activity in a rat model of neuropathic pain with n...
Ibipinabant is a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and peripheral cannabinoid (CB2), respectively.
Drinabant is a highly potent, selective antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM.
Rosonabant is a CB1 receptor antagonist/inverse agonist originated by Esteve. It is an appetite suppressant for the treatment of obesity. But development of the...
AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 ...
WIN 55212-2 mesylate
The mesylate salt form of WIN 55212-2, an aminoalkylindole derivative, is a CB receptor agonist and could be effective against some inflammatory reponse. IC50: ...
ACEA is a selective cannabinoid receptor 1 (CB1R) agonist (Ki = 1.4 nM) with much higher affinity over CB2R. CB1 receptors are mainly expressed in the central a...
BAY 38-7271, also called as KN 38-7271, is a cannabinoid receptor agonist with analgesic and neuroprotective effects. The doses of BAY 38-7271 in animals needed...
Iodopravadoline, also known as AM630, is an inverse agonist at the human cannabinoid CB1 receptor. Iodopravadoline has been found to attenuate the ability of a ...
AM1248 is an adamantoylindole derivative acts as a moderately potent agonist for both the cannabinoid receptors CB1 and CB2.
Otenabant, also known as CP-945,598, is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesi...
Levonantrado is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. Levonantrado is around 30x more potent than THC, and exhibits ant...